Introduction
oxidative damage and greater dopaminergic cell death in response to the neurotoxin MPTP whereas elevated PGC-1␣ expression protects neural cells from oxidative stress [8] . Another study suggests that down-regulation of PGC-1␣ expression leads to mitochondrial dysfunction and neurodegeneration in patients with Huntington's disease (HD) [9] . This evidence provides a connection between impaired energy metabolism and neurodegeneration in PD and HD and suggests that stimulating mitochondrial biogenesis by PGC-1␣ might be a promising strategy for the prevention of PD. However, no studies have been carried out on this mechanism underlying the beneficial effects of anti-PD drugs/agents.
We address three questions in this paper: first, whether a combination of mitochondrial antioxidants/nutrients has an advantage over individual application in preventing PD; second, if it is necessary to optimize the doses of the combined agents; and third, whether the stimulation of mitochondrial biogenesis by PGC-1␣ is a possible underlying mechanism for their preventative effects.
We selected LA and ALC for study. LA is a disulfide compound that is found naturally in mitochondria as a coenzyme for pyruvate dehydrogenase and ␣-ketoglutarate dehydrogenase [10] . LA is also a powerful antioxidant and a potent inducer of the phase 2 antioxidant enzyme that raises cellular antioxidant defence [4, 11] . [12] . Though ALC has proved to protect against MPTP-induced toxicity in murine neuroblastoma cells [13] and monkeys [14] , and LA has been implicated in the treatment of PD in both PC-12 cells [15] and mouse models [16] Fig. 1-4 
ALC is an acetyl derivative of L-carnitine, which facilitates the entry and exit of essential fatty acids from the mitochondria. Studies suggest it has a direct or indirect antioxidant activity

Detection of oxidant generation
Oxidant generation was detected using 2Ј,7Ј-dichlorodihydrofluorescein (DCFH) [21] [22] .
Determination of ␣-synuclein and ubiquitin levels
Distribution of ␣-synuclein and ubiquitin was determined by immunofluorescence labelling [17] [23] .
Western blotting analysis of complex I and PGC-1␣ protein expression
Protein expression of complex I and PGC-1␣ was detected using Western blotting with primary antibodies directed against PGC-1␣ (1:1000) or complex I (1:2000) and with horseradish peroxidase-conjugated secondary antibody.
Statistical analysis
One-way ANOVA 
Results
Four-week pretreatment with LA and/or ALC counteracted the rotenone-induced mitochondrial dysfunction
Much evidence suggests a major role for mitochondrial dysfunction in the pathogenesis of PD, in particular, defects in mitochondrial complex I of the respiratory chain [1, 2] . As depicted in Figure 1A 
The mitochondrial respiratory chain produces energy that is stored in the form of mitochondrial membrane potential (MMP).
This energy is then able to drive the synthesis of ATP. Therefore, diminished mitochondrial function will lead to decreased MMP and a fall in ATP synthesis [24] . We determined MMP using 5,5',6,6'-tetrachloro-1,1',3,3 Figure 1B ( [25] [26] [27] . We examined the production of reduced glutathione (GSH), an important endogenous antioxidant, and oxidative damage to protein and DNA. As indicated in Figure 2A, [17] , and the comet assay, a single cell-based technique that allows the researcher to detect and quantify DNA damage [22] . As shown in Figure 3 , rotenone-alone treated cells showed increased 8-oxo-dG immunoreactivity (Fig. 3A) and a much higher tail moment value (Fig. 3B) , compared to control cells (P Ͻ 0.001 
'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1). JC-1 can selectively enter into mitochondria and reversibly change colour from green to red as the MMP increases. As shown in
LA and/or ALC stimulated mitochondrial biogenesis, up-regulated the expression of PGC-1 ␣ and reduced the production of ROS during the 4-week pretreatment
Since LA and ALC were withdrawn after a 4-week pretreatment, the question arose as to whether they actively enhanced the antioxidant defence systems for cells to be resistant to the ensuing 4-week rotenone challenge. Defective mitochondrial function and impaired energy metabolism are highly implicated in the pathogenesis of PD [8]. Thus, the stimulation of mitochondrial biogenesis might be a promising strategy for PD prevention. We evaluated three aspects of mitochondrial biogenesis: number of viable mitochondria, mitochondrial DNA (mtDNA) and the protein expression of complex I, the most important mitochondrial protein involved in PD pathogenesis.
MitoTracker fluorescence was used to assess viable mitochondria. As depicted in Figure 5A, Figure 5B . Figure 5E, of mitochondrial biogenesis (8, 9) . As shown in Figure 6A (Western blotting image) and Figure 6B ( Figure 6C 
The D-loop is known as the major site of transcription initiation on both the heavy and light strands of mtDNA. We evaluated the D-loop using real-time PCR with 18SrRNA, a nuclear-encoded gene, as control. As shown in
Discussion
We propose that, in order to prevent PD with high levels of efficacy and safety, mitochondrial nutrients should be combined, and they should be patient, and it remains unclear which are primary, which are secondary and how they interact in leading to the degenerative process [1, 26] . Therefore, combined agents that focus on the various aetiologic and pathogenetic factors would be extremely helpful. A combination of mitochondrial nutrients may effectively complement one another in defending the system against mitochondrial dysfunction and oxidative damage [3] . We have demonstrated in previous studies that in aged rats, LA and ALC were more efficient in combination than individually in ameliorating mitochondrial decay with age, inhibiting oxidative damage, and improving cognitive function and ambulatory activity [29] [30] [31] . This evidence strongly supports the general concept of determining optimal combinations of mitochondrial nutrients for better neuroprotective effects.
The development of PD is a lengthy process [32, 33] 
